Capital Fund Management (CFM)’s Myriad Genetics MYGN Stock Holding History

Capital Fund Management (CFM)’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-12,000	Closed	-$412K	–	2063
2017 Q4	$412K	Buy	+12,000	New	+$405K	﹤0.01%	1523
2015 Q1	–	Sell	-14,500	Closed	-$494K	–	1635
2014 Q4	$494K	Hold	14,500	–	–	0.01%	1138
2014 Q3	$559K	Sell	14,500 -6,000	-29%	-$224K	0.01%	1116
2014 Q2	$798K	Buy	20,500 +800	+4%	+$29.8K	0.01%	1048
2014 Q1	$674K	Buy	+19,700	New	+$610K	0.01%	1108
2013 Q3	–	Sell	-83,400	Closed	-$2.24M	–	1787
2013 Q2	$2.24M	Buy	+83,400	New	+$2.42M	0.03%	596

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Capital Fund Management (CFM)'s MYGN Position: Q2 2025 in Review

Capital Fund Management (CFM) sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 44,917 shares — an estimated $398K sold.

Capital Fund Management (CFM) first reported a position in MYGN in Q4 2013 and held it in 7 quarters. The position peaked at $2.94M in Q2 2016. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

Capital Fund Management (CFM) reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
Capital Fund Management (CFM) sold 44,917 Myriad Genetics shares in Q2 2025, an estimated $398K.
Capital Fund Management (CFM) first reported a position in Myriad Genetics in Q4 2013 and held it in 7 quarters.
Capital Fund Management (CFM)'s Myriad Genetics position peaked at $2.94M in Q2 2016.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2025, filed 13 Aug 2025.